Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · NutriBand Inc. (NTRB)

Nutriband selects brand name for its abuse deterrent fentanyl patch

Neutral Impact 2 of 5 product/contract Written later

Nutriband said in a March 30, 2026 press release that it has selected a commercial brand name for its lead product, an abuse deterrent fentanyl transdermal system, and will submit the name to the FDA for approval. The filing does not report revenue, earnings, or guidance, and the company's $80 million to $200 million peak annual US sales estimate is a potential figure, not a forecast, so the news is a development step toward regulatory review.

Key points

  • Nutriband partnered with Brand Institute, Inc. on the brand name, and its subsidiary Drug Safety Institute will provide regulatory support on the project.
  • The proposed name and labeling will go to the FDA and other international regulators, and the name is being submitted to the USPTO for trademark registration.
  • The company says the product has the potential to reach peak annual US sales of $80 million to $200 million, citing a 2022 market analysis report.

The filing

CompanyNutriBand Inc. (NTRB)
Form8-K, current report
Filed with the SECApr 7, 2026, 3:43 PM ET
Accession number0001213900-26-041006

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on April 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.